Result for
Tag: vaccine
June 7, 2021
Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination
Reports from seven cases of acute myocarditis (inflammation of the heart) or myopericarditis among adolescent males who developed chest pain within four days of receiving the Pfizer-BioNTech vaccine and were hospitalized found that six of seven patients had negative SARS-CoV-2 nucleocapsid antibody assays (indicating no prior infection), and all patients’ symptoms resolved quickly. Three patients…
Adverse Events Following MRNA SARS-CoV-2 Vaccination among U.S. Nursing Home Residents
No major safety problems were detected following the first or second dose of either of the two mRNA SARS-CoV-2 vaccines in a study of electronic health records from US nursing home residents (n = 8,553) between December 18, 2020 and March 7, 2021. The analysis of pre-specified adverse events did not detect statistical signals for…
May 27, 2021
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
The efficacy in preventing symptomatic COVID-19 14 days after the second dose for two inactivated SARS-CoV-2 vaccines (derived from strains WIV04 and HB02) was 73% (95% CI, 58%-82%) and 78% (95% CI, 65%-86%), respectively, in an interim analysis of a randomized, placebo-controlled phase 3 trial among adults aged ≥18 years without known prior infection in…
May 26, 2021
Single-Dose SARS-CoV-2 Vaccine in a Prospective Cohort of COVID-19 Patients
[Pre-print, not peer-reviewed] A study comparing antibody responses in 155 previously SARS-CoV-2 infected individuals found a single dose of the Pfizer-BioNTech vaccine provided neutralizing antibody titers exceeding those produced following two vaccine doses in 49 previously uninfected healthcare workers. Additionally, pre-vaccination neutralization titers in persons with previous infection were associated with higher neutralization titers after…
Influence of Past Infection with SARS-CoV-2 on the Response to the BioTech Pfizer BNT162b2 MRNA Vaccine in Health Care Workers Kinetics and Durability of the Humoral Response
[Pre-print, not peer-reviewed] A cohort study of 63 hospital healthcare workers in Spain who received 2 doses of the Pfizer-BioNTech vaccine found that those with a previous SARS-CoV-2 infection developed a 126-fold increase in antibody levels after 1 dose and maintained higher antibody levels than SARS-CoV-2 naïve workers after the 2nd dose. Healthcare workers with…
May 25, 2021
Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series
In a case series of 36 participants from the UK with persistent COVID-19 symptoms 8 months after hospitalization, 71% of reported symptoms present prior to vaccination with a COVID-19 vaccine were unchanged a median of 1 month after receiving the first dose. 23% of symptoms had improved, and 6% had worsened. Prior to vaccination, participants…
May 21, 2021
Infection and Vaccine-Induced Neutralizing Antibody Responses to the SARS-CoV-2 B.1.617.1 Variant
[Pre-print, not peer-reviewed] An in-vitro study of neutralizing antibody response to the B.617.1 variant found that the variant was 6.8-fold more resistant to neutralization by sera from persons previously infected with SARS-CoV-2 (N=24) and individuals vaccinated with either the Pfizer-BioNTech (N=10) or Moderna (N=15) vaccines compared to a wild type strain. However, 79% of serum…
May 17, 2021
Seroconversion Rates Following COVID-19 Vaccination amongst Patients with Malignant Disease- the Impact of Diagnosis and Cancer-Directed Therapies
[Pre-print, not peer-reviewed] Among patients with cancer (n = 201) who were fully vaccinated with the Pfizer-BioNTech, Moderna, or Johnson & Johnson/Janssen vaccines, the majority (94%) showed seroconversion for anti-spike protein IgG. Lower seroconversion frequencies were observed for patients with hematological malignancies (85%), particularly recipients of anti-CD20 therapies (70%) and stem cell transplantation (74%), compared…
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-Elicited and Therapeutic Monoclonal Antibodies
[Pre-print, not peer-reviewed] The SARS-CoV-2 B.1.617 and B.1.618 strains currently circulating in India were found to have specific spike protein mutations (B.1.617 = L452R/E484Q/D614G/P681R, B.1.618 = Δ145-146/E484K/D614G) that were somewhat resistant to neutralization by sera from convalescent individuals, vaccine-elicited antibodies, and therapeutic monoclonal antibodies; but not enough to suggest that current vaccines will not be…
Cellular Immunity Predominates over Humoral Immunity after the First Dose of COVID-19 Vaccines in Solid Organ Transplant Recipients
[Pre-print, not peer-reviewed] Among solid organ transplant recipients (n = 40) and age-matched controls (n = 70), antibodies were detected in only 5% of transplant recipients versus 80% of controls, though specific CD4 and/or CD8 T-cells were more frequently found in both transplant recipients (24%) and controls (84%). IgG and neutralization activity were also higher…
Previous page Next page